产品详情
简单介绍：
Anti-SAP155抗体产品质量稳定，实验效果明显，货期快，价格优惠，欢迎垂询订购！我公司长期供应**组化抗体、WB抗体、**组化试剂盒和抗体试验所需全部相关试剂、荧光标记抗体、单克隆抗体、多克隆抗体、各种标记的二抗IgG/IgM/IgD/IgA等科研实验抗体。Anti-SAP155抗体用于**组化实验,WB实验,相应的标记抗体有HRP标记抗体,FITC标记,BIO等。
详情介绍：
Rabbit Anti-SAP155
Cat. Number:
Anti-SAP155抗体KL-7417R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
SAP 155 is a 1,304 amino acid member of the SF3B1 family and contains eleven HEAT repeats. Localized to nuclear speckles and also to the cytoplasm during mitosis, SAP 155 is a subunit of the SF3B splicing factor. The SF3B splicing factor is a U2 snRNP-associated protein complex essential for spliceosome assembly.
Anti-SAP155抗体SF3B contains the spliceosomal proteins SAP 49, SAP 130, SAP 145 and SAP 155. Concomitant with splicing catalysis, SAP 155 is phosphorylated at its N-terminal Thr-Pro dipeptide motifs by Dyrk1A and cyclin E/Cdk2. This modification of SAP 155 is vital for a functional spliceosome as it is an essential event in the basic splicing reaction. Due to alternative splicing events, various SAP 155 isoforms are produced.
Also known as:
Hsh 155; MDS; Pre mRNA
Anti-SAP155抗体processing 10; Pre mRNA splicing factor SF3b 155 kDa subunit; PRP 10; PRP10; PRPF 10; PRPF10; SAP 155; SAP155; SF3B 1; SF3B 1; SF3b155; Spliceosome associated protein 155; Splicing factor 3b subunit 1 155kDa; Splicing factor 3B subunit 1; SF3B1_HUMAN.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, .
●
Immunogen: KLH conjugated
Anti-SAP155抗体synthetic peptide derived from huuman SAP155/SF3B1.
●
Predicted Molecular Weight: 146kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500
Anti-SAP155抗体
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
